Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine

Primary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against symptomatic infection in adults, and 75.1% efficacy in participants previously infected with COVID-19 Against Omicron, sequencing analysis performed to date shows 72% efficacy in all adults and 93.2% in seropositives Favorable safety and tolerability profile

Related Keywords

United Kingdom ,Thomas Triomphe ,Roger Connor ,Us Department Of Health ,Human Services ,Biomedical Advanced Research ,National Institute Of Allergy ,Clinical Trials Group Leadership ,Development Authority ,Data Management Center ,Infectious Diseases Clinical Research Consortium ,Nuclear Defense Under Contract ,Laboratory Center ,Operations Center ,Prevention Trials Network Leadership ,Vaccine Trials Network ,London United Kingdom ,Executive Vice President Vaccines ,Assistant Secretary ,Defense Joint Program Executive Office ,Nuclear Defense ,National Institute ,Infectious Diseases ,Trials Network ,Trials Network Leadership ,Trials Group Leadership ,Raids ,Alliance ,Artificial Intelligence ,Clinical Research ,Influenza ,Nasdaq ,Pharmaceuticals ,Vaccination ,Vaccine ,Covid 19 Vaccination In The United States ,Covid 19 Vaccine ,H5n1 Vaccine Clinical Trials ,Hiv Vaccine Development ,Rna Vaccines ,Sanofi ,Sanofi Gsk Covid 19 Vaccine ,